CoChat

Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug

Open access
Xu, Xiaoyang, Xie, Kun, Zhang, Xue-Qing, Pridgen, Eric M., Park, Ga Young, Cui, Danica S., Shi, Jinjun, Wu, Jun, Kantoff, Philip W., Lippard, Stephen J., Langer, Robert, Walker, Graham C., Farokhzad, Omid C. · 2013 · Proceedings of the National Academy of Sciences

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Abstract

Significance: The development of acquired chemoresistance is often a clinical problem limiting the successful treatment of cancers. RNAi is showing promising results in human clinical trials. The combination of chemotherapy with RNAi approaches to suppress the expression of proteins involved in the emergence of drug resistance represents a promising synergistic strategy to circumvent or reverse acquired chemoresistance. Such combination therapy approaches require specific delivery vehicles to encapsulate and deliver chemotherapy and siRNA therapeutics simultaneously in a controlled manner. Herein, we describe a nanoparticle technology to codeliver a DNA-damaging chemotherapeutic and siRNAs that impair the cell’s ability to repair the DNA damage. This combination therapeutic approach can sensitize cancer cells to chemotherapeutics and shows superior tumor inhibition compared with monochemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1303958110

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. Ryan CJ (2013) Clinical trial design strategies in the post-abiraterone/enzalutamide setting. 2013 Genitourinary Cancers Symposium Proceedings ed Carducci MA (American Society of Clinical Oncology Alexandria VA) pp 26–28.

Cited by

See all 346

Metadata

Authors
Xu, X., Xie, K., Zhang, X.-Q., Pridgen, E. M., Park, G. Y., Cui, D. S., Shi, J., Wu, J., Kantoff, P. W., Lippard, S. J., Langer, R., Walker, G. C., & Farokhzad, O. C.
Affiliations
  • Brigham and Women's Hospital (US)
  • Northwestern University (US)
  • Massachusetts Institute of Technology (US)
  • Harvard University (US)
  • The David H. Koch Institute for Integrative Cancer Research and
Venue
Proceedings of the National Academy of Sciences
Published
2013-10-28
Volume
110
Issue
46
Pages
18638-18643
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2158787062
Cited by
340
References
32
Citations by year
2026: 10 · 2025: 15 · 2024: 18 · 2023: 23 · 2022: 27 · 2021: 37 · 2020: 33 · 2019: 25 · 2018: 26 · 2017: 31 · 2016: 32 · 2015: 44 · 2014: 17 · 2013: 2
FWCI
14.18
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
Funders
  • National Cancer Institute (F32CA168163, R00CA160350, U54CA151884, CA151884, K99CA160350, R01CA034992)
  • National Institute of Environmental Health Sciences (ES-015818, R56ES015818, R01ES015818)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
cisplatin prodrug, siRNA delivery, nanoparticle drug delivery, co-delivery, translesion synthesis, Rev1, REV3L, acquired chemoresistance, DNA-damaging chemotherapy, synergistic antitumor effect, siRNA knockdown
MeSH terms
Antineoplastic Agents, Cisplatin, Drug Carriers, Drug Therapy, Combination, Humans, Luciferases, Platinum, Drug Delivery Systems, Drug Resistance, Neoplasm, Gene Silencing, RNA Interference, RNA, Small Interfering, Cell Line, Tumor, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. https://app.cochat.ai/papers/10.1073/pnas.1303958110
The paper
Xu, X., Xie, K., Zhang, X.-Q., Pridgen, E. M., Park, G. Y., Cui, D. S., Shi, J., Wu, J., Kantoff, P. W., Lippard, S. J., Langer, R., Walker, G. C., & Farokhzad, O. C. (2013). Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1303958110

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.